OSSIO has expanded its product lineup with the launch of OSSIOfiber small compression staples, targeting hand and foot procedures, particularly bunion repair through the Akin osteotomy technique.
The American orthopedic fixation company is engaged in developing bio-integrative fixation implants that leave no permanent residue. The company received US Food and Drug Administration (FDA) clearance for the new staples in November 2023.
The OSSIOfiber small compression staples enhance OSSIO’s portfolio, which includes larger compression staples, suture anchors, trimmable fixation nails, compression screws, and a hammertoe fixation system.
These implants utilise a bio-integrative fiber matrix designed for ease of use and compression strength that matches or exceeds nitinol staples, all without permanent implantation.
OSSIO CEO Brian Verrier said: “Our mission at OSSIO is nothing less than transforming the experience of patients who must undergo orthopedic surgery where internal fixation is required.
“With more than 40,000 OSSIOfiber implants performed to date, just five years since commercialising our first product in 2019, we launch this new small compression staple platform, further expanding patient access to a metal-free alternative for orthopedic fixation.”
Indicated for arthrodesis, osteotomies, and fractures in hand or foot surgery with appropriate bracing or immobilisation, the OSSIOfiber small compression staples must be adapted in number and size to specific surgical needs.
These implants rely on Intelligent Bone Regeneration Technology, which addresses the limitations of permanent metal hardware and conventional absorbable implants by offering unparalleled mechanical strength and natural bone healing.
Made from a proprietary mineral fibre matrix bonded by a bio-friendly polymer, OSSIOfiber implants promote rapid bone in-growth, regeneration, and replacement.
This first-of-its-kind implant material is claimed to be stronger than cortical bone, ensuring functional fixation and complete integration into the patient’s anatomy without adverse biological responses.
OSSIO plans to extend the application of OSSIOfiber implants across major orthopedic segments. These include foot and ankle, hand and wrist, upper extremity and trauma, pediatrics, sports medicine, and reconstruction, by manufacturing various implant designs such as nails, screws, staples, anchors, and plates.
